
Sign up to save your podcasts
Or


Joshua D. Moss, MD, FHRS, of University of California, San Francisco is joined by guests Thomas A Dewland, MD, FHRS, of University of California, San Francisco, and Nathaniel Steiger, MD, of Brigham and Women's Hospital to discuss Utility and Limitations of Ablation Index for Guiding Therapy in Ventricular Myocardium. The Ablation Index (AI) has limited value for guiding ablation in ventricular myocardium, particularly scar. This may be related to small proportional significance of application duration and complex tissue architecture.
https://www.hrsonline.org/education/TheLead
https://www.jacc.org/doi/10.1016/j.jacep.2023.03.020
Host Disclosure(s):
J. Moss: Honoraria/Speaking/Consulting Fee: Biosense Webster, Farapulse, Haemonetics, Baylis Medical, Abbott; Stocks (Publicly Traded): Doximity, Moderna Therapeutics
Contributor Disclosure(s):
T. Dewland: Honoraria/Speaking/Consulting Fee: Adagio Medical
N. Steiger: No relevant financial relationships with ineligible companies to disclose.
By The Lead Podcast presented by Heart Rhythm Society5
77 ratings
Joshua D. Moss, MD, FHRS, of University of California, San Francisco is joined by guests Thomas A Dewland, MD, FHRS, of University of California, San Francisco, and Nathaniel Steiger, MD, of Brigham and Women's Hospital to discuss Utility and Limitations of Ablation Index for Guiding Therapy in Ventricular Myocardium. The Ablation Index (AI) has limited value for guiding ablation in ventricular myocardium, particularly scar. This may be related to small proportional significance of application duration and complex tissue architecture.
https://www.hrsonline.org/education/TheLead
https://www.jacc.org/doi/10.1016/j.jacep.2023.03.020
Host Disclosure(s):
J. Moss: Honoraria/Speaking/Consulting Fee: Biosense Webster, Farapulse, Haemonetics, Baylis Medical, Abbott; Stocks (Publicly Traded): Doximity, Moderna Therapeutics
Contributor Disclosure(s):
T. Dewland: Honoraria/Speaking/Consulting Fee: Adagio Medical
N. Steiger: No relevant financial relationships with ineligible companies to disclose.

320 Listeners

498 Listeners

169 Listeners

885 Listeners

3,344 Listeners

140 Listeners

9,137 Listeners

195 Listeners

364 Listeners

431 Listeners

371 Listeners

29,209 Listeners

4 Listeners

3 Listeners

0 Listeners